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 The basic principle for the diagnosis of melanoma metastases in the brain should be the management of multidisciplinary 
teams including at least a neurosurgeon, radiotherapist and clinical oncologist experienced in the treatment of melanoma 
and melanoma metastases in the CNS. Detection of brain lesions is associated with poor prognosis; metastases in the brain 
are the cause of death in 20–50% patients, and symptomatic tumours are a direct cause of death in about 90% patients. 
Treatment of melanoma with CNS metastases may include local management and/or systemic and symptomatic treat-
ment. In the last 5 years, 10 new advanced melanoma drugs have been registered in Europe. Two-drug therapy anti-PD-1 
and anti-CTLA-4 (nivolumab with ipilimumab) is the treatment of choice for asymptomatic melanoma metastases in the 
brain, while in the presence of BRAF mutations and asymptomatic metastases systemic treatment with BRAFi and MEKi 
may be the first-choice treatment.
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Introduction
In terms of the frequency of metastases in the brain, melanoma 
is the third most common malignant tumour after breast and 
lung cancer. It is estimated that in the course of advanced me-
lanoma in about 50–60% patients the disease will spread to the 
brain (including about 75% patients with multiple metastases, 
often initially asymptomatic). In autopsy about 75% of patients 
have metastases in the brain. At the moment of diagnosis of 
melanoma, 7% of patients have metastases in the brain. In 
3% of patients with diagnosed metastatic lesions in the brain, 
the primary lesion cannot be found. It should be noted that 
only in 8–46% melanoma patients metastatic tumours in the 
brain are found in vivo, and in 94% of them they are the direct 
cause of death. 
In the latest classification of melanoma severity according 
to American Joint Committee on Cancer (AJCC; eighth edition) 
metastases in the brain were distinguished as a separate, last 
category in the fourth stage of melanoma severity – M1d. [1]. 
The risk of metastases in the brain increases with the grade of 
melanoma [2]. Currently, there are no predictive possibilities to 
determine the risk of metastases in the central nervous system 
(CNS) in patients with melanoma. However, it is known that 
some factors contribute to a higher risk of metastases in the 
CNS (primary lesion in the head and neck, increased activity of 
lactate dehydrogenase (LDH), ulceration in the primary lesion, 
mutations in the BRAF, NRAS and PTEN genes) [3].
The occurrence of brain lesions is associated with poor 
prognosis. Metastases in this part of the CNS contribute to 
death in 20–50% patients and symptomatic tumours are the 
direct cause of death in about 90% patients. Historical data 
show that the overall survival (OS) median after the diagnosis 
of brain metastasis is within 5–7 months, whereas in patients 
with symptoms of the disease treated with whole brain radio-
therapy (WBRT), which is currently rarely used, the OS median 
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was 2–5 months. In patients undergoing surgical treatment 
or stereotactic radiosurgery (SRS)/radiosurgery, the median 
overall survival was twice as long [4]. 
The aim of this paper is to present multidisciplinary guide-
lines for diagnostic and therapeutic management in patients 
with melanoma with brain metastases, as it is currently the 
greatest challenge in the care of advanced stage melanoma. 
New therapies introduced into everyday clinical practice 
have made the current management of metastatic melanoma 
little in common with clinical practice 5 years ago. More and 
more often metastases in the brain are diagnosed before their 
symptoms appear, after routine brain imaging (magnetic re-
sonance imaging – MRI and/or computed tomography – CT) 
during the follow-up or qualification of the patient for systemic 
treatment. Advanced techniques of stereotactic radiotherapy 
play a fundamental role in local treatment. In the last 5 years 
10 new drugs for advanced melanoma therapy have been 
registered in Europe: vemurafenib, dabrafenib, trametinib, 
cobimetinib, binimetinib, encorafenib, ipilimumab, nivolu-
mab, pembrolizumab and talimogen laherparepvec (T-VEC). 
In Poland, 7 new drugs are currently available under drug pro-
grammes: vemurafenib, cobimetinib, dabrafenib, trametinib, 
ipilimumab, pembrolizumab and nivolumab. For both pembro-
lizumab/nivolumab and combined therapy with BRAF (BRAFi) 
and MEK (MEKi) inhibitors, in the whole group of patients with 
metastatic melanoma with the presence of BRAF mutation, 
the median OS based on clinical data is now about 2 years 
(i.e. about 4 times longer than 5 years ago). Perhaps the best 
results can be achieved with dual-drug immunotherapy (anti-
-CTLA-4 and anti-PD-1), as shown by the preliminary results 
of studies, or other combined therapies (e.g. T-VEC + pembro-
lizumab) or even iBRAFi, MEKi with anti-PD-1 or anti-PD-L1. 
Therefore, whenever metastases in the brain are confirmed, it is 
necessary to investigate the presence of BRAF gene mutation in 
the fixed material (if this has not been previously evaluated) [5, 6]. 
The basic and post-metastatic management of melanoma 
in the brain should be carried out in multidisciplinary teams, 
whose members have experience in the diagnosis and tre-
atment of melanoma. Such a team should include at least: 
neurosurgeon, radiotherapist and clinical oncologist [7]. 
Diagnostics 
Objective and subjective symptoms of CNS metastases may 
be subtle and difficult to recognize. They depend, among 
other things, on the number, size and location of metastases. 
Metastases are most often formed in the telencephalon, then 
(about 15% of them), are located in the cerebellum and (about 
5%) in the brain stem. The most common symptoms of these 
lesions are:
• headaches, sometimes accompanied by nausea and/or 
vomiting, 
• epileptic seizures, 
• speech, comprehension and vision disturbances, 
• numbness, 
• mobility disorders. 
The occurrence of clinical symptoms of metastases in the 
CNS is associated with worse treatment outcome. Melanoma 
patients in stage I and II are less likely to develop metastases in 
the CNS than patients in stage III and IV patients [8]. In younger 
patients the risk of late metastases in CNS in case of thicker 
primary lesions is higher [9]. Based on data from retrospective 
analysis carried out in a large multi-centre S0008 study, the risk 
of metastases in the CNS in patients with melanoma at the 
stage of IIIB and IIIC is 15% – they were found mainly during 
the first 3 years after surgery[10]. The time from the treatment 
of the primary lesion can be relatively long and can be as long 
as 3–4 years (median) [11]. 
Therefore, in patients with melanoma at III and IV stage 
of advancement, it is important to detect metastases in CNS 
on the basis of control imaging tests, despite the absence of 
clinical symptoms. Performing MRI of CNS during the evalu-
ation of disease progression after the diagnosis of melanoma 
in the fourth stage should be the standard of management. 
In patients with melanoma at the stage of IIIC and higher 
without tumour symptoms, CT or MRI of the CNS should be 
considered [6]. In the case of patients with objective and/or 
subjective symptoms, even of minor severity, which indicate 
the possibility of CNS lesions, MRI should be performed [12]. 
It is the most sensitive in terms of metastasis detection in CNS 
and has an advantage over contrasting CT. Unfortunately, MRI 
is less accessible and more expensive, so it can be considered 
a necessary complementary study in patients:
•  with confirmed CNS metastases – to obtain the informa-
tion necessary to determine the further course of action 
(number and/or location of lesions) and 
• with clinical symptoms with no change in contrasting 
CT [13].
It should be emphasized that metastases of melanoma in 
the CNS are characterized by a tendency to occur in the plural 
and a tendency to bleed [14]. 
Therapeutic management
The therapeutic management depends on the clinical situation 
and includes systemic, local (radiotherapy/SRS and/or surgery) 
or symptomatic treatment. In the treatment of melanoma me-
tastases in the CNS, apart from clinical symptoms, numerous 
parameters related to the disease and the patients themselves 
play an important role, such as:
• number, size and location of metastases, 
• presence and control of lesions outside the CNS, 
• previous treatment of melanoma and its outcome, 
• the presence of a mutation in the BRAF gene, 
• the patient’s general condition, his or her age, 
• comorbidities and their treatment.
In the symptomatic treatment of melanoma metastases 
in the CNS, anti-swelling drugs are used, mainly glucocorti-
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costeroids, but also diuretics (loop diuretics, mannitol). In the 
event of an epileptic seizure, antiepileptic treatment should 
be instituted, bearing in mind interactions with other drugs 
used in the patient, including glucocorticosteroids. 
Tables I and II summarize two prognostic scales used in 
patients with CNS metastases, where the recursive partitioning 
analysis (RPA) scale refers to all neoplasms and the diagno-
sis-specific graded prognostic assessment (DS-GPA) scale to 
melanoma patients only. 
It should be remembered, however, that these scales were 
developed before the introduction of new systemic therapies 
for the treatment of generalised melanoma. Updated scales 
also include the status of BRAF gene mutation and the presen-
ce of metastases outside the brain.
The pattern of management in patients with melanoma 
with CNS metastases is presented in figure 2. 
Local treatment of melanoma metastases in the 
brain
In patients with symptomatic metastatic melanoma lesions 
in the brain, the expected survival without treatment is 2–3 
months, and only 13% of OS patients will survive longer than 
one year (better prognosis in patients under 65 years of age and 
with Karnofsky Performance Scale (KPS) >70 points). Prognosis 
is affected by the removal or irradiation of all metastatic lesions. 
Leaving one of several lesions causes the prognosis to be the 
same as in the absence of treatment [16]. 
There are still no clear predictive factors for the occurrence 
of melanoma metastases in the CNS. It is known, however, that 
certain factors are associated with increased risk. These include, 
but are not limited to:
• primary lesion within the head and neck,
• increased LDH activity,
• ulceration in the primary lesion,
• molecular changes in BRAF, NRAS and PTEN [3]. 
In patients with metastases in the brain, mutations in the 
BRAF gene occur in 24–58% cases and in 23% in the NRAS gene.
Surgical treatment
Eligibility criteria for surgical treatment of melanoma metasta-
ses in the brain (Evidence Based Medicine [EBM], 2010, level 1):
• newly discovered, single lesions up to 4,  
• the size of the lesion prevents SRS (diameter greater than 
3 cm),
• the location of the lesion is surgically accessible,
• symptomatic tumours causing:
– neurological deficit and/or
– increased intracranial pressure due to its volume and/
or accompanying haemorrhage and/or secondary 
obstruction of the fluid pathways leading to hydro-
cephalus (lesions in the posterior cranial fossa),
• efficiency according to KPS >70, age <65 years,
• progression after prior stereotactic irradiation.
Objectives of surgical treatment:
• histological verification of the lesion,
• radical excision of all lesions, which affects OS (no justi-
fication for biopsy) – in case of multiple tumours, hybrid 
therapy (resection of large, surgically accessible lesions in 
combination with SRS for smaller tumours located in deep 
brain structures) is possible,
• improvement or stabilization of neurological condition 
(occurrence of new neurological deficits shortens OS by 
4 months),
• enabling further oncological treatment,
• resection of symptomatic radionecrosis after SRS.
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Figure 1. Kaplan-Meier survival curves for individual groups on the GPA 
scale [16]
Table I. RPA (recursive partitioning analysis; n = 1200) [15] 
Class I Class II Class III
KPS ≥70 ≥70 <70
Primary lesion Controlled Active Active
Age <65 65 Any
Extracranial disease No Present Present
Incidence 15% 65% 20%
Median OS (months) 7.1 4.2 2.3
Table II. Prognostic assessment of the survival of melanoma patients with 
brain metastases – DS-GPA scale (diagnosis-specific graded prognostic 
assessment) [16] 
KPS (points) <70 70–80 90-100
Number of metastases 
within the CNS
3 2–3 1
Points 0 1 2
Division based on the sum of the number of points awarded for KPS and 
the number of metastases (including the patient’s age: >60 years – 0, 
50–60 years – 0.5 and <50 years – 1.0)
DS-GPA 0–1.0 1.5–2.0 2.5–3.0 3.5–4.0
Median OS 
(months)
3.4 4.7 8.8 13.2
The median survival rate of all patients with melanoma was 6.74 months 
(range 3.38–13.32 months; n = 481)
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Radiotherapy 
Stereotactic radiation therapy (radiosurgery)
Stereotactic irradiation is the delivery of a biologically high 
dose of radiation to a precisely defined small volume with 
a significant drop in the dispersed dose outside the target 
area. Treatment can be performed with one fractional dose 
(radiosurgery) or 3–5 fractions (fractionated stereotactic ra-
diotherapy). Irradiation can be carried out with equipment 
designed for such treatment (Gamma Knife, Cyber Knife, EDGE), 
as well as with conventional linear accelerators equipped with 
high-resolution leaf collimators. The prescribed total dose and 
the choice of fractionation scheme depends on the location 
of metastatic lesions and their volume. 
To achieve high local efficacy, a total dose should be 
administered that is more than 100 Gy after conversion to 
a biologically effective dose (BED). The efficacy of SRS in the 
treatment of small metastases of melanoma in the brain has 
been confirmed in many studies and is similar to that achieved 
by metastasectomy. The most important is the appropriate 
qualification of patients for treatment, which should be carried 
out in multidisciplinary teams. 
The rules for qualifying for the SRS are as follows:
• the general condition of the patient: WHO 0–2,
• a single metastasis with a diameter of <3 cm, 
• the number of metastases >1 where the total volume 
of the healthy brain irradiated with 12 Gy dose does not 
exceed 10 cm3,
• no progression of changes outside the CNS or availability 
of potentially effective systemic treatment,
• irradiation of the postoperative bed [17, 18],
• possible local repeated irradiation after progression has 
been detected, 
• life expectancy >6 months.
Recently, the indications for SRS have been extended; 
it was originally reserved for patients with no more than 3 
metastases [22–24]. Ideally, the number of lesions should not 
exceed 5, but none of them should exceed 3 cm in diameter. 
However, a cautious qualification of patients who do not meet 
these assumptions is possible [19]. 
Nowadays, the number of metastases is of lesser impor-
tance and a limitation for stereotactic radiation is the volume 
of all lesions and the volume of the brain receiving a total 
dose of 12 Gy [25, 26]. It has been demonstrated that a healthy 
brain volume of more than 10 cm3 receiving a 12 Gy dose is 
associated with a high risk of radionecrosis. In such clinical 
situations, reduction of the therapeutic dose or disqualification 
of the patient from stereotactic irradiation and qualification 
for WBRT should be considered, especially in the presence of 
multiple metastases. If properly qualified, local efficacy of SRS 
(no progression in irradiated volume) is achieved at 90–95% 
patients with melanoma [20, 21]. Moreover, in half of the pa-
tients a radiologically significant tumour response is observed 
[20]. The local efficacy is closely linked to the location of the 
lesion and its size. 
Whole brain radiotherapy
Melanoma is considered to be a radiation-resistant neoplasm 
and sensitive only to higher fractional doses. Fractionation 
schemes used to irradiate the whole brain (whole brain radio-
therapy, WBRT; 5 × 4 Gy, 10 × 3 Gy) do not provide a biological 
dose that allows for long-term control of the disease within the 
CNS. In addition, WBRT is associated with neurological toxicity. 
The deterioration of the quality of life of patients is caused 
mainly by cognitive dysfunction [27, 28]. Therefore, the WBRT 
should be reserved exclusively for patients:
• with a predicted short survival time,
• in poor general condition: WHO 3–4, 
• disqualified from a surgery and SRS,
• with a large volume of neoplastic lesions within the CNS, 
• with their rapid progression and in case of lack of possibility 
of effective systemic treatment, 
• with metastases in the meninges, in good general con-
dition.
Patients in very poor general condition (performance sta-
tus: WHO 4) with symptoms of brain oedema that do not yield 
to anti-oedematous treatment should be disqualified from 
any form of radiotherapy. The management of choice is then 
symptomatic treatment, such as effective anti-oedema and 
antiepileptic management, as well as treatment of symptoms 
often associated with progression within the CNS.
The results of phase III study published in 2019 indicate 
that WBRT as a supplementary treatment after local treatment 
of melanoma metastases within the CNS does not improve the 
results of the therapy. The whole brain radiotherapy should the-
refore be reserved for patients disqualified from local treatment.
Systemic treatment
Systemic treatment is the basis of the management of pa-
tients with disseminated melanoma, including patients with 
brain metastases. Similarly as in the case of molecularly targe-
ted therapy (BRAF and MEK inhibitors [BRAFi and MEKi]), the 
use of immunotherapy, including anti-CTL-A4 and anti-PD-1 
drugs, significantly improves the prognosis of melanoma 
patients with metastases to the CNS. More and more long-
-term remissions are observed in patients responding to 
immunotherapy [29]. Depending on the previous treatment, 
the presence of V600 BRAF mutation and the patient’s con-
dition and clinical situation, appropriate systemic therapy 
should be implemented, in most cases supplemented by 
local treatment. In a situation of a few small metastases in 
the CNS, exclusive systemic treatment remains an option. 
Blood-brain barrier is not important for the activity of new 
drugs used in the therapy of melanoma.
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Molecularly targeted therapy
The efficacy of molecularly targeted drugs (BRAF/MEK inhibi-
tors) in patients with brain metastases of skin melanoma has 
been confirmed in several prospective clinical studies. The first 
clinical trials conducted exclusively in this group of patients 
evaluated the effectiveness of BRAFi used in monotherapy. 
In the largest study, including as many as 172 patients with 
asymptomatic metastases, the efficacy of dabrafenib (study 
phase II BREAK-MB) was assessed. The patients participating 
in the study were divided into two groups based on the pre-
vious local treatment due to brain metastases (without prior 
local treatment vs. progression after prior local treatment). The 
intracranial response rates were 39.2% and 30.8%, respectively. 
The median OS in both groups was more than 8 months [2]. In 
a similar clinical trial on the use of vemurafenib in 146 patients 
with skin melanoma with brain metastases (phase II trial), the 
intracranial response rate was 18% regardless of previous local 
treatment. The median OS was about 9 months [30]. If we take 
into account the assessment of responses by an indepen-
dent review committee (IRC), the intracranial response rates 
in both studies were very similar (about 18%). These studies 
also showed a relatively high percentage of disease control 
(about 70–80%). This is due to the fact that in the majority of 
patients the reduction of metastatic lesions in the brain was 
observed, but only in some of them did it meet the criterion 
of partial response. 
A difficult clinical situation is the presence of symptomatic 
metastases in the brain. This stage of disease is associated with 
particularly poor prognosis (median OS 3–4 months). The only 
clinical trial that included only this group of patients concerned 
the use of vemurafenib in monotherapy [31]. It was a study 
with a small number of patients: 24 patients not eligible for 
neurosurgery were included, after previous treatment of brain 
metastases and requiring the use of glucocorticosteroids to 
control symptoms. The percentage of intracranial responses 
was 16% and the median OS – 5.3 months. During treatment, 
a reduction in pain symptoms was observed, as well as im-
provement of patients’ performance status, and reduction of 
the need for glucocorticoids. Unfortunately, the effect of the 
treatment was short-lived and the disease progressed rapidly. 
The improvement of targeted treatment results was bro-
ught about by the combination therapy of BRAFi with MEKi. 
The only prospective clinical study evaluating the activity of 
this therapy in patients with metastases in the brain is phase 
II of COMBI-MB using dabrafenib and trametinib [32]. 125 
patients with performance status 0–2 according to Eastern 
Cooperative Oncology Group (ECOG) with or without prior 
treatment of local metastases in the brain were enrolled to the 
study. The intracranial response rate was 56–59%, regardless 
of the previous local treatment and presence of symptomatic 
metastases. Longer duration of response was observed in 
patients with asymptomatic brain metastases. The median 
duration of the response was, however, considerably shorter 
than that observed in phase III clinical trials without the parti-
cipation of patients with brain metastases (about 6 months vs. 
12–14 months) [33–35]. No significant differences in treatment 
tolerance were observed. The most common side effects were 
fever and gastrointestinal disorders. 
The results of the studies mentioned above confirm the 
activity of BRAFi/MEKi in patients with brain metastases. The 
response to treatment is rapid, and the reduction in tumour 
lesions occurs in the majority of patients. This is not only im-
portant for improvement of OS in this group of patients with 
poor prognosis, but also to improve the quality of life. This is 
particularly true for patients with symptomatic brain metasta-
ses. Unfortunately, the above data also indicate a short-term 
therapeutic effect of targeted treatment. Resistance in this 
group of patients appears faster than in patients without me-
tastases in the brain. Therefore, in order to improve treatment 
outcome, attempts are currently being made to combine 
BRAFi/MEKi with other kinase inhibitors or immunotherapy. 
The results of BRAFi/MEKi tests in patients with melanoma 
with CNS metastases are presented in table III. 
Radiotherapy in combination with targeted 
therapy
High initial BRAFi/MEKi activity in patients with melanoma with 
brain metastases has slightly changed the approach to the 
use of radiotherapy. The increasingly widespread use of SRS 
gives a high percentage of local disease control. However, it 
has not been shown to protect against further spread of the 
disease within the CNS and therefore, with the exception of 
patients with isolated brain metastases, has little effect on OS. 
Therefore, radiotherapy is often used only during the treatment 
of BRAFi/MEKi. 
The data on the purposefulness of combining BRAFi drugs 
with simultaneous irradiation are contradictory. On the one 
hand, the potential benefits of such a strategy in terms of 
sensitisation of melanoma cells to radiotherapy after BRAFi, 
as described in in vitro studies, are pointed out [36]. On the 
other hand, the radiation-sensitising BRAFi action can lead 
to increased side effects, which has been confirmed by se-
veral described case studies of significant skin toxicity during 
simultaneous use of a combination of irradiation with these 
drugs, also WBRT. So far, a similar radiosensitizing effect has 
not been described after the simultaneous use of BRAFi with 
MEKi. There is no clear evidence of an increased risk of neuro-
toxicity, haemorrhage or brain radiation necrosis in the com-
bination of targeted treatment with radiotherapy [37–39]. The 
combination of targeted treatment with radiosurgery to the 
CNS area gives fewer side effects than the combination with 
conventional radiotherapy. For conventional radiotherapy, the 
most common adverse reaction is skin toxicity (more severe 
with vemurafenib) [40].
Irradiation during targeted therapy increases the risk of 
dermatitis in degree II and III. As the severity of inflammation 
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depends on the irradiation dose, doses ≥4 Gy for conventional 
radiotherapy are not recommended. It is currently recommen-
ded to stop using BRAFi and MEKi at least 3 days before the 
irradiation and to re-activate the drugs at the earliest 3 days 
after its completion [37]. The exception is SRS for CNS, in which 
case a sufficient break in the use of BRAFi and MEKi before and 
after radiotherapy is one day.
Immunotherapy
Immunotherapy is the primary option in patients with mela-
noma with CNS metastases in the absence of V600 mutation 
in the BRAF gene. In patients with BRAF mutation, the choice of 
immunotherapy or treatment with BRAFi from MEKi depends 
on the clinical situation. 
In an open-label phase II of clinical trial with ipilimumab 
(NCT00623766), the highest response rates were observed 
in asymptomatic patients who did not receive steroids. On 
the basis of immune related response (IRR) criteria, the me-
dian  progression-free survival (PFS) of CNS lesions was 1.9 
months in the asymptomatic group vs. 1.2 months in a group 
requiring glucocorticosteroids due to clinical symptoms of 
CNS metastases, and OS, respectively, 7.0 vs. 3.7 months [41]. 
In the CheckMate 204 (NCT02320058) study with nivolumab 
and ipilimumab, which enrolled patients with at least one CNS 
lesion, the primary endpoint was intracranial clinical benefit 
rate (CBR) – a complex endpoint including complete response 
(CR), partial response (PR) and stable disease (SD) for more than 
6 months. The intracranial objective response rate (ORR) was 
55% and CR was 21%. Extracranial responses were similar to 
those observed in the CNS, and the PFS rate at six months of 
treatment was 67%. The results of this study confirm that simi-
larly to the treatment of extracranial disease, in patients with 
CNS metastases it is possible to obtain a similar response to 
the treatment of CNS lesions [41]. In 2019, updated CheckMate 
2004 results from two cohorts of patients were presented. The 
A cohort included persons without neurological symptoms, 
not taking steroids (a cohort of patients with asymptomatic 
brain metastases), and the B cohort included persons with 
neurological symptoms – regardless of whether they received 
steroids or not. Patients from both groups received nivolumab 
(NIVO) at a dose of 1 mg/kg of body weight + ipilimumab (IPI) 
at a dose of 3 mg/kg b.w., every 3 weeks, 4 doses followed by 
NIVO at a dose of 3 mg/kg b.w. every 2 weeks – to the onset of 
disease progression or toxicity of treatment. In cohort A after 
the follow-up period of 20.6 months CBR amounted to 58.4%, 
while in cohort B after the follow-up period of 5.2 months it 
amounted to 22.2%. Level III and IV treatment-related adverse 
events were observed in 54% of patients in cohort A and 56% of 
patients in cohort B. Level III and IV nervous system related ad-
verse events occurred in 7% and 17% of patients, respectively. 
Similarly, in the Australian ABC study (NCT02374242), in which 
the efficacy of nivolumab versus nivolumab plus ipilimumab 
in melanoma patients with brain metastases (n  = 79) was 
investigated, the efficacy of immunotherapy was demonstra-
ted, including the advantage of dual therapy in melanoma 
patients with asymptomatic brain metastases. In this study, 
the patients were assigned to three cohorts: cohort A (n = 36, 
a group of asymptomatic patients without local treatment due 
to brain metastases, receiving ipilimumab with nivolumab); 
cohort B (n = 27, group of asymptomatic patients without 
local treatment due to metastases to the CNS, receiving nivo-
lumab); and cohort C (n = 16, patients after local treatment 
Table III. Studies on the effectiveness of molecularly targeted therapy in the treatment of melanoma with metastases in the CNS
Study Characteristics of patients Number of 
patients
PFS 
(median, 
months)
OS 
(median, 
months)
Phase II study [30]
(NCT01378975)
vemurafenib
Previously untreated CNS metastases
Previously treated, CNS metastases
90 
56 
3.7
4.0
8.9
9.6
Pilot study [31] (NCT01253564) 
vemurafenib
Previously treated, symptomatic 
metastases in CNS 
24 3.9 5.3
Phase II study BREAK-MB [2]
(NCT01266967)
dabrafenib
CNS metastases without prior treatment 
Progression after prior local treatment
89
83
∼4 a
∼4 a
∼8 a
∼8 a
Phase II study
COMBI-MB [32]
(NCT02039947)
dabrafenib + trametinib 
Asymptomatic CNS metastases without 
prior local treatmentECOG PS 0–1
Asymptomatic CNS metastases; prior 
local treatment ECOG PS 0–1
Asymptomatic metastases with/without 
prior local treatment ECOG PS 0–1
Symptomatic metastases
with/without prior local treatment
ECOG PS 0–2
76
16
16
17
5.6
7.2
4.2
5.5
10.8
24.3
10.1
11.5
a Median refers to patients with the presence of BRAF V600E mutation
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due to brain metastases failure and symptomatic patients with 
brain metastases and patients with leptomeningeal disease, 
receiving nivolumab). Complete responses to treatment were 
observed in 17% of patients in cohort A, 12% in cohort B, and 
none in cohort C [42]. In the CheckMate 204 study and in the 
ABC study, grade 3 and 4 treatment-related adverse events in 
patients receiving dual therapy occurred in 52% and 54% of 
patients, respectively. 
In asymptomatic patients, the efficacy and good toleran-
ce of immunotherapy were confirmed by the clinical trials 
presented. The response rate for ipilimumab was 16% and for 
nivolumab and pembrolizumab about 20%. In the study of 
the combination of anti-PD-1 and anti-CTLA-4 in the group 
of asymptomatic patients, further significant improvement in 
treatment results was achieved. In patients with symptomatic 
metastases the clinical response rate was also significant and 
amounted to 16.7%. In the situation of the availability of com-
bination therapy with anti-PD-1 plus anti-CTLA-4 (nivolumab 
with ipilimumab) and in the case of good performance status 
of the patient, this combination is the treatment of choice 
for asymptomatic melanoma patients with brain metastases. 
The results of clinical studies with immunotherapy in pa-
tients with melanoma brain metastases are summarised in 
table IV.
Combination of radiotherapy with 
immunotherapy
There are more and more reports related to beneficial effect 
of combining radiotherapy with immunotherapy. The studies 
published so far show a significant increase in the percentage 
of the phenomenon called abscopal effect (response of untre-
ated lesions to local treatment of other lesions) after radiothe-
rapy was added to immunotherapy [46]. This is explained by 
local stimulation of the immune system and enhancement 
of the antigenic effect, where dendritic cells probably play 
a major role. There are many clinical trials underway in which 
radiotherapy and immunotherapy are combined. There are 
no contraindications for combining SRS/WBRT with immu-
notherapy, the decision should be made at a multidisciplinary 
meeting for each patient individually. Attention should be paid 
to the accompanying radiotherapy prophylactic anti-oede-
ma treatment in the form of high doses of glucocorticoids 
that can reduce the efficacy of immunotherapy. According 
to current recommendations, the indications for the use of 
glucocorticosteroids in anti-oedema treatment during SRS 
are significantly limited. 
The combination of immunotherapy or molecularly tar-
geted therapy with SRS seems to be generally well tolerated, 
as demonstrated by studies and analyses conducted so far. 
In 2016, the results of the retrospective analysis done in the 
subgroup of patients participating in two prospective studies 
with nivolumab for unresectable or metastatic disease were 
published [47]. The analysis included 26 patients treated with 
melanoma and treated with SRS due to CNS metastases, inc-
luding patients with CNS metastases diagnosed and treated 
with SRS within 6 months of treatment with nivolumab (before, 
after or during immunotherapy). A total of 73 CNS lesions 
were identified in these patients. The primary endpoint of 
the analysis was treatment tolerability, and secondary endpo-
ints were intracranial disease control and extracranial disease 
Table IV. Studies on the effectiveness of immunotherapy in the treatment of patients with melanoma with CNS metastases
Treatment Patients Characteristics 
of patients
IC DCR IC ORR IC DOR  
(months)
mPFS 
(months)
mOS 
(months)
IPI CA184–042 
[41]
51 (A) 
21 (B)
Asymptomatic 
Symptomatic
24% 
10%
16% 
5%
_ 1.4 
1.2
7.0 
3.7
IPI + fotemustine 
NIBIT-M1 [43]
20 Asymptomatic 50% 40% 30.3 4.5 12.7
Pembrolizumab 
(NCT02085070) 
[44]
18 Untreated or 
progressive bra-
in metastases
44% 22% – – NR
NIWO: ABC; 
CA209–170 [42]
(NCT02374242)
27 (B) 
 
16 (C)
Asymptomatic, 
no local treat-
ment (B) 
Prior treatment 
or symptoma-
tic (C)
20% 
 
19%
20% 
 
6%
NR 
 
NR
2.5 
 
2.3
18.5 
 
5.1
NIWO + IPI: ABC; 
CA209–170
36 (A) Asymptomatic, 
no local treat-
ment (A)
57% 46% NR NR NR 
NIWO + IPI: 
CheckMate 
204 [45] 
(NCT02320058)
75 Asymptomatic, 
prior treatment, 
≤3 metastases
60% 55% NR NR –
NR – not reached
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control as well as OS. The majority of metastases were treated 
with single-fraction radiosurgery, only 12 CNS lesions were 
treated with fractionated SRS. In one patient headaches of 
grade 2 were observed, which disappeared after steroids were 
applied. No other neurological complications associated with 
the treatment were observed. In case of 8 CNS lesions (11%) 
failure of treatment in the form of increase of their volume by 
at least 20% was observed. Local control rates after six and 12 
months were, respectively, 91% and 85%. The median OS was 
12.0 months from the beginning of treatment with nivolumab 
and 11.8 months from SRS. 
In 2017 a systematic review devoted to the evaluation of 
the tolerance of combined immunotherapy or molecularly 
targeted therapy with SRS was published. In the overview six 
retrospective studies and two case studies of patients treated 
with SRS and ipilimumab were included. Based on the analysis 
of these data, combination therapy with ipilimumab and SRS 
for intracranial lesions can be considered as a safe method of 
treatment [48]. 
New systemic treatment methods 
Due to the often short-term or insufficient response to systemic 
treatment of melanoma patients with CNS metastases after 
immunotherapy or molecularly targeted therapy, attempts 
are now being made to combine BRAF/MEK inhibitors with 
other kinase inhibitors or immunotherapeutic agents. The 
objective is to improve treatment outcomes. One such study 
is the TRIDeNT study using nivolumab in combination with 
dabrafenib and/or trametinib, which may involve patients 
with metastases to the CNS and patients with melanoma with 
leptomeningeal metastases (NCT02910700) [49].
Monitoring patients after local treatment 
of CNS metastases and management in case 
of progression 
Patients undergoing surgery or SRS should be monitored by 
performing a brain magnetic resonance imaging to quickly 
detect possible progression within the CNS. The first MRI sho-
uld be performed within one month after surgery/SRS, and 
the next every 2–3 months. The imaging test results should 
be interpreted with caution, especially in patients undergoing 
immunotherapy due to the possibility of pseudoprogression 
and changes after treatment, which can be difficult to di-
stinguish from disease progression. Metastases of melanoma 
in the CNS increase the risk of new metastases in the CNS, 
hence the need to monitor the CNS by means of MRI [6]. In 
about 50% of patients new metastatic lesions or progression 
of metastases previously treated (relapse in the tumour bed, 
progression after SRS/WBRT) will be detected [50]. However, 
these are not situations disqualifying from further therapy. In 
such a situation, one of the rescue methods of local treatment 
(surgery, SRS, WBRT) can usually be applied after the patient’s 
case has been discussed at a multidisciplinary meeting [51–53]. 
After confirmation of the progression of CNS lesions after 
SRS or radiotherapy, while retaining the previously described 
eligibility criteria for neurosurgical treatment, surgical treat-
ment remains the therapy of choice. Despite the introduction 
of modern neuroimaging techniques, it may be difficult to 
determine whether the observed progression is secondary 
to active neoplastic process or secondary to radionecrosis. In 
doubtful cases, the treatment of choice should be resection 
of the lesion, because apart from oncological indications, the 
removal of dead tissues has an antioedematous effect.
Leptomeningeal metastases 
Prognosis in this group of patients is poor, the survival time 
usually does not exceed a few weeks. Data on the effectiveness 
of modern systemic treatment in the case of metastases to the 
meninges are limited and scientific evidence-based standards 
of management are lacking. Results of recently published re-
trospective analyses indicate that molecularly targeted therapy 
and immunotherapy may improve prognosis in these patients 
[54, 55]. A phase I clinical trial (NCT03025256) is currently being 
conducted using nivolumab, intravenous and intrathecal, in 
patients with leptomeningeal disease. 
The data concerning the systemic use of IL-2 are enco-
uraging; the 1-, 2- and 5-year survival rates in the group of 43 
patients were 36%, 26% and 13% respectively. However, in view 
of the increased toxicity, Il-2 is not considered as a standard 
procedure [56].
Radiotherapy in the form of WBRT including meninges up 
to C2 level is a palliative treatment and should be used only in 
a selected group of patients (good performance status, active 
systemic treatment).
Summary
The basic and binding principle for the diagnosis of melanoma 
metastases in the brain should be the management carried 
within multidisciplinary teams including at least a neurosur-
geon, radiotherapist and clinical oncologist experienced in the 
treatment of melanoma and melanoma metastases in the CNS. 
Predictive factors of metastases in CNS in melanoma patients 
have not been determined yet. Detection of brain lesions is 
associated with poor prognosis; metastases in the brain are the 
cause of death in 20–50% patients, and symptomatic tumours 
are a direct cause of death in about 90% patients. Historical 
data indicated the median OS after the diagnosis of brain 
metastasis was within 5–7 months. Nowadays, more and more 
often metastases in the brain are detected at the asymptomatic 
stage using routine brain imaging during patient follow-up or 
staging evaluation before systemic treatment. 
Treatment of melanoma with CNS metastases includes, 
depending on the clinical situation, local and/or systemic 
treatment and symptomatic treatment. Advanced SRS tech-
niques currently play a key role in local treatment. In the last 5 
years, 10 new advanced melanoma drugs have been registered 
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in Europe. Thanks to the introduction of modern systemic 
treatment, the median OS on the basis of clinical trial data is 
currently about 2 years. If anti-PD-1 and anti-CTLA-4 (nivolu-
mab with ipilimumab) are available as well as if the patient is 
in good condition, this is the procedure of choice for asymp-
tomatic melanoma metastases in the brain, while in the case 
of BRAF mutations and asymptomatic metastases, systemic 
BRAFi and MEKi treatment can be the first-choice treatment. 
In every case of melanoma metastases in the brain, individual 
multidisciplinary assessment of the patient with neurosurgeon, 
radiotherapist and clinical oncologist is necessary. The sum-
mary of management in patients with melanoma with CNS 
metastases is presented in figure 2. 
Conflict of interests: Piotr Rutkowski has received hono-
rariums for lectures and Advisory Board from Novartis, BMS, 
MSD, Roche, Amgen, Pierre Fabre.
Piotr Rutkowski
Maria Skłodowska-Curie Institute – Oncology Center
Department of Soft Tissue/Bone Sarcoma and Melanoma
ul. Roentgena 5,
02-781 Warszawa, Poland
e-mail: piotr.rutkowski@coi.pl
Received and accepted: 4 Sep 2019
References
1. Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma of the skin. AJCC 
Cancer Staging Manual. Eight Edition. Springer 2017.
2. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val-
600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain 
(BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 
2012; 13: 1087–1095.
3. Ramakrishna N, Margolin KA. Multidisciplinary approach to brain 
metastasis from melanoma; local therapies for central nervous system 
metastases. Am Soc Clin Oncol Educ Book. 2013; 399–403.
4. Davies MA, Liu P, McIntyre S et al. Prognostic factors for survival in mela-
noma patients with brain metastases. Cancer. 2011; 117: 1687–1696.
5. Rutkowski P, Wysocki P, Nasierowska-Guttmejer A et al. Cutaneous 
melanomas. Oncol Clin Pract. 2017; 13: 241–258.
6. NCCN Guidelines. Melanoma version 3.2018. 
7. Tawbi HA, Boutros C, Kok D et al. New era in the management of 
melanoma brain metastases. ASCO Educational Book. 2018; 741–750.
8. Zakrzewski J, Geraghty LN, Rose AE et al. Clinical variables and primary 
tumor characteristics predictive of the development of melanoma 
brain metastases and post-brain metastases survival. Cancer. 2011; 
117: 1711–1720.
9. Osella-Abate S, Ribero S, Sanlorenzo M et al. Risk factors related to late 
metastases in 1,372 melanoma patients disease free more than 10 years. 
Int J Cancer. 2015; 136: 2453–2457.
10. Samlowski WE, Moon J, Witter M et al. High frequency of brain me-
tastases after adjuvant therapy for high-risk melanoma. Cancer Med. 
2017; 6: 2576–2585.
11. Salvati M, Cervoni L, Caruso R et al. Solitary cerebral metastasis from 
melanoma: value of the ‘en bloc’ resection. Clin Neurol Neurosurg. 
1996; 98: 12–14.
12. Fink KR, Fink JR. Imaging of brain metastases. Surg Neurol Int. 2013; 
4: S209–219.
13. Premkumar A, Marincola F, Taubenberger J et al. Metastatic melanoma: 
correlation of MRI characteristics and histopathology. J Magn Reson 
Imaging. 1996; 6: 190–194.
14. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol 
Rep. 2012; 14: 48–54.
15. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) 
of prognostic factors in three Radiation Therapy Oncology Group 
(RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37: 
745–751.
16. Sperduto PW, Kased N, Roberge D et al. Summary report on the graded 
prognostic assessment: an accurate and facile diagnosis-specific tool 
to estimate survival for patients with brain metastases. J Clin Oncol. 
2012; 30: 419–425.
17. Ling DC, Vargo JA, Wegner RE et al. Postoperative stereotactic radio-
surgery to the resection cavity for large brain metastases: clinical 
outcomes, predictors of intracranial failure, and implications for op-
timal patient selection. Neurosurgery. 2015; 76: 150–156; discussion 
156–157; quiz 157.
18. Choi CY, Chang SD, Gibbs IC et al. Stereotactic radiosurgery of the 
postoperative resection cavity for brain metastases: prospective 
evaluation of target margin on tumor control. Int J Radiat Oncol Biol 
Phys 2012; 84: 336–342.
19. Minniti G, Paolini S, D’Andrea G et al. Outcomes of postoperative 
stereotactic radiosurgery to the resection cavity versus stereotactic 
radiosurgery alone for melanoma brain metastases. J Neurooncol. 
2017; 132: 455–462.
20. Mori Y, Kondziolka D, Flickinger JC et al. Stereotactic radiosurgery for 
cerebral metastatic melanoma: factors affecting local disease control 
and survival. Int J Radiat Oncol Biol Phys. 1998; 42: 581–589.
21. Yu C, Chen JC, Apuzzo ML et al. Metastatic melanoma to the brain: 
prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol 
Biol Phys. 2002; 52: 1277–1287.
22. Salvetti DJ, Nagaraja TG, McNeill IT et al. Gamma knife surgery for the 
treatment of 5 to 15 metastases to the brain: clinical article. J Neurosurg. 
2013; 118: 1250–1257.
23. Rava P, Leonard K, Sioshansi S et al. Survival among patients with 
10 or more brain metastases treated with stereotactic radiosurgery. 
J Neurosurg. 2013; 119: 457–462.
24. Yamamoto M, Serizawa T, Shuto T et al. Stereotactic radiosurgery for pa-
tients with multiple brain metastases (JLGK0901): a multi-institutional 
prospective observational study. Lancet Oncol. 2014; 15: 387–395.
25. Skeie BS, Skeie GO, Enger PO. Gamma knife surgery in brain melano-
mas: absence of extracranial metastases and tumor volume strongest 
indicators of prolonged survival. World Neurosurg. 2011; 75: 684–691; 
discussion 598–603.
26. Hunter GK, Suh JH, Reuther AM et al. Treatment of five or more brain 
metastases with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 
2012; 83: 1394–1398.
27. Li J, Bentzen SM, Li J et al. Relationship between neurocognitive func-
tion and quality of life after whole-brain radiotherapy in patients with 
brain metastasis. Int J Radiat Oncol Biol Phys. 2008; 71: 64–70.
28. Welzel G, Fleckenstein K, Schaefer J et al. Memory function before 
and after whole brain radiotherapy in patients with and without brain 
metastases. Int J Radiat Oncol Biol Phys. 2008; 72: 1311–1318.
29. Sloot S, Chen YA, Zhao X et al. Improved survival of patients with 
melanoma brain metastases in the era of targeted BRAF and immune 
checkpoint therapies. Cancer. 2018; 124: 297–305.
30. McArthur GA, Maio M, Arance A et al. Vemurafenib in metastatic mela-
noma patients with brain metastases: an open-label, single-arm, phase 
2, multicentre study. Ann Oncol. 2017; 28: 634–641.
31. Dummer R, Goldinger SM, Turtschi CP et al. Vemurafenib in patients 
with BRAF(V600) mutation-positive melanoma with symptomatic 
brain metastases: final results of an open-label pilot study. Eur J Cancer. 
2014; 50: 611–621.
32. Davies MA, Saiag P, Robert C et al. Dabrafenib plus trametinib in patients 
with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): 
a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 
2017; 18: 863–873.
33. Long GV, Flaherty KT, Stroyakovskiy D et al. Dabrafenib plus trametinib 
versus dabrafenib monotherapy in patients with metastatic BRAF 
V600E/K-mutant melanoma: long-term survival and safety analysis of 
a phase 3 study. Ann Oncol. 2017; 28: 1631–1639.
34. Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib 
versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: 
a  multicentre, double-blind, phase 3 randomised controlled trial. 
Lancet. 2015; 386: 444–451.
35. Robert C, Karaszewska B, Schachter J et al. Three-year estimate of overall 
survival in COMBI-v, a randomized phase 3 study evaluating first-line 
dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or 
metastatic BRAF V600E/K-mutant cutaneous melanoma. Ann Oncol. 
2016; 27 (suppl 6): 552–87 (abstr LBA40).
96
36. Ugurel S, Thirumaran RK, Bloethner S et al. B-RAF and N-RAS mutations 
are preserved during short time in vitro propagation and differentially 
impact prognosis. PLoS One. 2007; 2: e236.
37. Anker CJ, Grossmann KF, Atkins MB et al. Avoiding severe toxicity 
from combined BRAF inhibitor and radiation treatment: consensus 
guidelines from the Eastern Cooperative Oncology Group (ECOG). Int 
J Radiat Oncol Biol Phys. 2016; 95: 632–646.
38. Ly D, Bagshaw HP, Anker CJ et al. Local control after stereotactic ra-
diosurgery for brain metastases in patients with melanoma with and 
without BRAF mutation and treatment. J Neurosurg. 2015; 123: 395–401.
39. Rompoti N, Schilling B, Livingstone E et al. Combination of BRAF in-
hibitors and brain radiotherapy in patients with metastatic melanoma 
shows minimal acute toxicity. J Clin Oncol. 2013; 31: 3844–3845.
40. Hecht M, Zimmer L, Loquai C et al. Radiosensitization by BRAF inhibitor 
therapy-mechanism and frequency of toxicity in melanoma patients. 
Ann Oncol. 2015; 26: 1238–1244.
41. Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with 
melanoma and brain metastases: an open-label, phase 2 trial. Lancet 
Oncol. 2012; 13: 459–465.
42. Long GV, Atkinson V, Lo S et al. Combination nivolumab and ipilimumab 
or nivolumab alone in melanoma brain metastases: a multicentre ran-
domised phase 2 study. Lancet Oncol. 2018; 19: 672–681.
43. Di Giacomo AM, Ascierto PA, Queirolo P et al. Three-year follow-up of 
advanced melanoma patients who received ipilimumab plus fotemus-
tine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II 
study. Ann Oncol. 2015; 26: 798–803.
44. Goldberg SB, Gettinger SN, Mahajan A et al. Pembrolizumab for patients 
with melanoma or non-small-cell lung cancer and untreated brain 
metastases: early analysis of a non-randomised, open-label, phase 2 
trial. Lancet Oncol. 2016; 17: 976–983.
45. Tawbi HA, Forsyth PAJ, Algazie AP et al. Efficacy and safety of nivolumab 
(NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) meta-
static to the brain: results of the phase II study CheckMate 204. J Clin 
Oncol. 2017; 35 (Suppl 15): abstr 9507. 3. Tawbi HA, Forsyth PA, Algazu 
A, in. Combined nivolumab and ipilimumab in melanoma metastatic 
to the brain. N Engl J Med 2018; 379: 722–730. 
46. Park SS, Dong H, Liu X et al. PD-1 restrains radiotherapy – induced 
abscopal effect. Cancer Immunol Res. 2015; 3: 610–619.
47. Ahmed KA, Stallworth DG, Kim Y et al. Clinical outcomes of melanoma 
brain metastases treated with stereotactic radiation and anti-PD-1 
therapy. Ann Oncol. 2016; 27: 434–441.
48. Kroeze SG, Fritz C, Hoyer M et al. Toxicity of concurrent stereotactic 
radiotherapy and targeted therapy or immunotherapy: A systematic 
review. Cancer Treat Rev. 2017; 53: 25–37.
49. ClinicalTrials.gov. Study of the anti-PD-1 antibody nivolumab in com-
bination with dabrafenib and/or trametinib in patients with BRAF or 
NRAS-mutated metastatic melanoma. https://clinical trials.gov/ct2/
show/NCT02910700.
50. Samlowski WE, Watson GA, Wang M et al. Multimodality treatment of 
melanoma brain metastases incorporating stereotactic radiosurgery 
(SRS). Cancer. 2007; 109: 1855–1862.
51. Noel G, Proudhom MA, Valery CA et al. Radiosurgery for re-irradiation of 
brain metastasis: results in 54 patients. Radiother Oncol. 2001; 60: 61–67.
52. Chao ST, Barnett GH, Vogelbaum MA et al. Salvage stereotactic radiosur-
gery effectively treats recurrences from whole-brain radiation therapy. 
Cancer. 2008; 113: 2198–2204.
53. Ammirati M, Cobbs CS, Linskey ME et al. The role of retreatment in the 
management of recurrent/progressive brain metastases: a systematic 
review and evidence-based clinical practice guideline. J Neurooncol. 
2010; 96: 85–96.
54. Geukes Foppen MH, Brandsma D, Blank CU et al. Targeted treatment 
and immunotherapy in leptomeningeal metastases from melanoma. 
Ann Oncol. 2016; 27: 1138–1142.
55. Smalley KS, Fedorenko IV, Kenchappa RS et al. Managing leptomenin-
geal melanoma metastases in the era of immune and targeted therapy. 
Int J Cancer. 2016; 139: 1195–1201.
56. Glitza IC, Rohlfs M, Guha-Thakurta N et al. Retrospective review of 
metastatic melanoma patients with leptomeningeal disease treated 
with intrathecal interleukin-2. ESMO Open. 2018; 3 (1): e000283.
